The challenge
The breast biopsy market was increasingly shaped by portfolio standardization, contracting complexity, and institutional purchasing dynamics. Competitors with expansive product suites were leveraging bundled agreements to influence purchasing decisions, raising the bar for differentiation.
The client’s prior assessments relied heavily on internal data, limiting visibility into how customers perceived the brand, evaluated value, and selected vendors. Leadership lacked a fact-based view of competitive positioning, portfolio gaps, and the commercial levers most likely to drive adoption.
With an imminent product launch, the organization needed to define a distinct go-to-market strategy grounded in real customer insight and aligned to evolving decision-making dynamics.
The solution
The client engaged BCE Consulting to deliver a comprehensive, evidence-based assessment of its breast biopsy business and launch strategy.
Using its Commercial Differentiators Framework, BCE evaluated performance across product features, pricing, contracting models, field resourcing, account support, and channel engagement. Structured market research captured direct customer perspectives on brand perception, decision drivers, and competitive trade-offs.
Customers were segmented by clinical priorities, economic influence, and standardization dynamics. BCE mapped competitor contracting approaches and identified structural opportunities to differentiate beyond product attributes alone. Launch best practices were embedded across market shaping, trial execution, onboarding, and post-launch sustainment.
Insights were translated into a refined value narrative, targeted account strategies, objection-handling playbooks, and practical launch tools designed to enable confident field execution.
The results
The engagement strengthened the client’s competitive positioning and materially improved launch readiness.
A differentiated value proposition clarified the brand’s role within evolving breast care pathways. Prioritized targeting ensured resources were focused on accounts with the highest adoption potential. Field teams were equipped with structured tools to navigate contracting discussions, clinical objections, and economic scrutiny.
The next-generation breast biopsy system launched with stronger positioning, clearer economic articulation, and improved adoption momentum. Beyond the launch, the commercial roadmap and organizational readiness initiatives established a foundation for sustained portfolio growth in an increasingly consolidated market.
